Glycerol, Iodinated

Summary

Glycerol, Iodinated (CHEMBL2105827) is an approved small molecule targeting TAS2R14.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• Targets: 1 (TAS2R14)
• Chemistry: 258.05 Da · C6H11IO3

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL2105827
Name	Glycerol, Iodinated
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	21852
Molecular formula	C6H11IO3
Molecular weight	258.05
InChIKey	LTINPJMVDKPJJI-UHFFFAOYSA-N

SMILES: CC(C1OCC(O1)CO)I

IUPAC name: [2-(1-iodoethyl)-1,3-dioxolan-4-yl]methanol

Also known as: Glycerol, iodinated, Iodinated glycerol, Iodopropylidene glycerol, GLYCEROL, IODINATED

Patent coverage: 226 distinct patent families (813 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

Gene	Target	Action	pAffinity	Cancer dependency	UniProt
TAS2R14	TAS2R14	Agonist	4.49	0.1%	Q9NYV8

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

Aggregated over 1 target gene(s): TAS2R14.

Top Reactome pathways

9 total, by targets touching each:

Pathway	Targets	Genes
Signal Transduction	1	TAS2R14
Signaling by GPCR	1	TAS2R14
GPCR downstream signalling	1	TAS2R14
G alpha (i) signalling events	1	TAS2R14
Class C/3 (Metabotropic glutamate/pheromone receptors)	1	TAS2R14
GPCR ligand binding	1	TAS2R14
Sensory Perception	1	TAS2R14
Sensory perception of taste	1	TAS2R14
Sensory perception of sweet, bitter, and umami (glutamate) taste	1	TAS2R14

Dominant GO biological processes

GO term	Targets
detection of chemical stimulus involved in sensory perception of bitter taste	1
G protein-coupled receptor signaling pathway	1
signal transduction	1
sensory perception of taste	1

Indications & clinical

Indications

0 indications (0 at ChEMBL trial phase 4).

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.

2 molecules share ≥1 primary target. Top 2 by shared-target count:

Molecule	Source	Status	Shared targets
ISOPROTERENOL	ChEMBL	Phase 4 (approved)	TAS2R14
FLUFENAMIC ACID	ChEMBL	Phase 2	TAS2R14